Hormonal ablation therapy for metastatic prostatic carcinoma : A review

Journal of the Medical Association of Thailand

Volumn 82, Issue 2, 1999, Pages 192-204

  Leewansangtong, Sunai ^a   Soontrapa, Suchai ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Hormonal Ablation Therapy; Metastatic Prostatic Carcinoma; Review

Indexed keywords

ANTIANDROGEN; ESTROGEN; GONADORELIN AGONIST;

CANCER HORMONE THERAPY; CASTRATION; HUMAN; MALE; METASTASIS; ORCHIECTOMY; PROSTATE CARCINOMA; REVIEW; STANDARD;

ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032913961     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Soontrapa S, Tantiwong A, Panawattanakul S, et al. Prostatatic carcinoma at Siriraj Hospital. Siriraj Hosp Gaz 1997; 49: 107-13.
2. Huggins C, Hodes CV. Studies of prostatic cancer. 1. The effects of castrations, of estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of prostate. Cancer Res 1941; 1: 293-307.
3. Bruchorsky N. Androgen and antiandrogens. In Holland JF, Frei EIII, Bast RC, et al (eds) : Cancer Medicine, 3rd. Philadelphia, Lea and Febiger, 1993: 884-96.
4. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991-8.
5. Schulz P, Bauer HW, Brade WP, Keller A, Fittler F. Evaluation of the cytotoxic activity of diethylstilbestrol and its mono and diphosphate towards prostatic carcinoma cells. Cancer Res 1988; 48: 2867-70.
6. Schulz P, Link TA, Chaudhuri L, Fittler F. Role of the mitochondrial bcl-complex in the cytotoxic action of diethylstilbestrol-diphosphate toward prostatic carcinoma cells. Cancer Res 1990; 50: 5008-12.
7. Robertson CN, Roberson KM, Padilla GM, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Nat Cancer Inst 1996; 88: 908-17.
8. Herbst WP. Effects of estradiol dipropionate and diethylstilbestrol on malignant prostatic tissue. Trans Amer Assn Genitourin Surg 1941; 34: 195.
9. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Nation Cancer Inst Monogr 1988; 7: 165-70.
10. Veterans' Administative Co-operative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011-7.
11. de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxy-progesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986; 135: 303-7.
12. Henriksson P, Edhag O. Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects. Br Med J 1986; 293: 413-5.
13. Robinson MR. A further analysis of European Organization for Research and Treatment of Cancer protocol 30805. Orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol. Cancer 1993; 72: 3855-7.
14. Morales A, Pujari B. The choice of estrogen preparations in the treatment of prostatic cancer. CMAJ 1975; 113: 865-7.
15. Bishop MC, Lemberger RJ, Selby C, Lawrence WT. Oestrogen dosage in prostatic cancer: the threshold effect?. Br J Urol 1989; 64: 290-6.
16. Bishop MC, Selby C, Taylor M. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine. Br J Urol 1985; 57: 542-7.
17. Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989; 33(suppl): 45-52.
18. Lukkarinen O, Kontturi M. Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study. Scand J Urol Nephrol 1994; 28: 171-8.
19. Garnick MB. Hormonal therapy in the management of prostate cancer: from Huggins to the present. Urology 1997; 49(Suppl 3A): 5-15.
20. Smith PH. Esrogens reconsidered. Semin Surg Oncol 1995; 11: 72-5.
21. Crawford ED, Eisenberger MA, McLeod DG, Wilding G, Blumenstein BA. Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate. Results of NCI intergroup study 0105 (SWOG and ECOG). J Urol 1997; 157: 336, Abs#1311.
22. Lin BJ, Chen KK, Chen MT, Chang LS. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastasis prostate cancer. Urology 1994; 43: 834-7.
23. Beland G, Elhilali M, Fradet Y, et al. Total androgen ablation: Canadian experience. Urol Clin North Am 1991; 18: 75-82.
24. Janknegt RA, Abbou CC, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149: 77-83.
25. Denis LJ, Carnelro de Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Croup and EORTC Data Center. Urology 1993; 42: 119-30.
26. Zhang XZ, Donovan MP, Williams BT, Mohler JL. Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer. Urology 1996; 47: 402-4.
27. Schally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 1971; 43: 393-9.
28. Labrie F, Belanger A, Simard J, Labrie C, Dupont A Combinatior therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 1993; 71: 1059-67.
29. Stenner J, Rosenblum M, Miller GJ, Crawford ED. Orchiectomy with or without flutamide: Is there still a place for combined androgen blockade in the therapy of advance prostate cancer? Urology Int 1997 (in press).
30. Leuprolide Study Group. Leuprolide versus diethyl-stilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281-6.
31. Klioze SS, Miller MF, Spiro TP. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients. Am J Clin Oncol 1988; 2(suppl): 5176-82.
32. Koutsilieris M, Faure N, Tolis G, Laroche B, Robert G, Ackman CF. Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome. Urology 1986; 27: 221-8.
33. Schroeder FH, Lock TM, Chadha DR, et al. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol 1987; 137: 912-8.
34. Isurugi K, Fukutani K, Ishida H, Hosoi Y. Endocrine effects of cyproterone acetate in patients with prostatic cancer. J Urol 1980; 123: 180-3.
35. Labrie F, Dupont A, Belanger A, Lachance R. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 1987; 138: 804-6.
36. Kuhn JM, Billebaud T, Navratil H, et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone agonist (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989; 321: 413-8.
37. Pinski J, Yano T, Miller G, Schally AV. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75. Prostate 1992; 20: 213-24.
38. Schroder FH. Cyproterone acetate mechanism of action and clinical effectiveness in prostate cancer treatment. Cancer 1993; 72: 3810-5.
39. Vener PM, Klotz PG, Kotz LH, et al. Megestrol acetate plus minidose diethylstibestrol in the treatment of carcinoma of prostate. Semin Oncol 1988; 15 (2 suppl1) : 62-7.
40. Patel SR, Kvols LK, Hahn RG, Windschilt LH, Levitt R, Therneau T. A phase II randomized trial of megestrol acetate or dexamethazone in the treatment of hormonally refractory advance carcinoma of the prostate. Cancer 1990; 66: 655-68.
41. Scott WW, Schirmer HK. A new oral progestational steroidal effective in treating prostatic cancer. Trans Am Assoc Genito-Urn Surg 1966; 58: 54-62.
42. Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial. Br J Urol 1980; 52: 208-15.
43. Pavone-Macaluso M, de Voogt HJ, Viggiano G, et al. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986; 136: 624-31.
44. Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O'Boyle PJ. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29: 47-54.
45. Goldenberg SL, Brushovsky NB. Use of cyproterone acetate in prostate cancer. Urol Clin North Am 1991; 18: 111-22.
46. Hugosson J, Abrahamsson PA, Ahlgren G, et al. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 1996; 29: 413-9.
47. Sogani PC, Vagaiwala MR, Whitmore WF Jr. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 1984; 54: 744-50.
48. Lund F, Rasmussen F. Flutamide versus stilbestrol in the management of advanced prostatic cancer, a controlled prospective study. Br J Urol 1988; 61: 140-2.
49. Migliari R, Muscas G, Usai E. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer. J Urol 1992; 148: 338-41.
50. Neri R, Florance K, Koziol P, Van Cleave S. A biological profile of a nonsteroidal antiandrogen, SCH (4′-nitro-3′trifluoromethylisobutyranilide). Endocrinol 1972; 91: 427-37.
51. Delaere KP, Van Thillo EL. Flutamide monotheraphy as primary treatment in advanced prostatic carcinoma. Semin Oncol 1991; 18: 13-8.
52. Prout GR Jr, Keating MA, Griffin PP, Schiff SF. Long-term experience with flutamide in patients with prostatic carcinoma. Urology 1989;34(suppl): 37-45.
53. Sogani PC, Whitmore WF Jr. Experience with flutamide in previously untreated patients with prostatic cancer. J Urol 1979; 122: 640-3.
54. Boccon-Gibod L. Nonsteroidal antiandrogen monotherapy of metastatic cancer of the prostate. Eur Urol 1993; 24 (suppl 2): 77-80.
55. Chang A, Yeap B, Davis T, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14: 2250-7
56. Wysowski DK, Freiman JP, Tourtelot JB, Horton ML 3d. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118: 860-4.
57. Mcload DG. Antiandrogenic Drug. Cancer 1993; 71 (3 suppl): 1046-9.
58. Decensi AU, Boccardo F, Guarneri D, et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 1991; 146: 377-81.
59. Gomez JL, Dupont A, Cusan L, Tremblay M, Lafrie F. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): case report. Amer J Med 1992; 92: 563-6.
60. Kolvenbag GJ, Blackledge GR, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate 1998; 34: 61-72.
61. Iversen P. Update of monotherapy trials with the new antiandrogen, casodex (ICI 176,334) Eur Urol 1994; 26 (suppl): 5-9.
62. Tyrrell CJ. Casodex: a pure non-steroidal antiandrogen used as monotherapy in advanced prostate cancer. Prostate 1992; 4 (suppl): 97-104.
63. Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995; 46: 849-55.
64. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996; 47(suppl 1A): 38-43.
65. Kaisary AV. Current clinical studies with a new nonsteroidal antiandrogen, Casodex. Prostate 1994; 5(suppl): 27-33.
66. Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982; 142: 2137-40.
67. Young FM, Luderer WB, Rodgers RJ. The antioxidant beta-carotene prevents covalent cross-linking between cholesterol side-chain cleavage cytochrome P450 and its electron donor, adrenodoxin, in bovine luteal cells. Mol Cell Endocrinol 1995; 109: 113-8.
68. Crawford ED. Hormonal therapy of prostatic carcinoma: Defining the challenge. Cancer 1990; 66 (suppl): 1035-8.
69. Harper ME, Pike A, Peeling WB, Griffiths K. Steroidals of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol 1974; 60: 117-25.
70. Geller J, Albert J, Loza D, Geller S, Stoeltzing W, de la Vega D. DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 1978; 46: 440-4.
71. Geller J, Albert JD, Nachtsheim DA, Loza D Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 1984; 132: 693-6.
72. Farnsworth WE, Brown JR. Androgen of the human prostate. Endocr Res Commun 1976; 3: 105-17.
73. Geller J, Albert J. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH). Urol Res 1987; 15: 151-3.
74. Labrie F. Intracrinology. Mol Cell Endocrinol 1991; 78: 113-8.
75. Huggins C, Scott WW. Bilateral adrenalectomy in prostatic cancer. Ann Surg 1945; 122: 1031-41.
76. Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial ablation of androgens. Prostate 1983; 4: 579-94.
77. Crawford ED, Blumenstein BA. Proposed substages for metastatic prostate cancer. Urology 1997; 50: 1027.
78. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24.
79. Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 1997; 158: 160-3.
80. Eisenberger MA, Crawford ED, Wolf M, et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study : 0036. Semin Oncol 1994; 21: 613-9.
81. Bertagna C, De Gery A, Hucher M, Francois JP, Zanirato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 1994; 73: 396-402.
82. Iversen P, Rasmussen F, Klarskov P, Christensen IJ. Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer 1993; 72; 3851-4.
83. Tyrrell CJ, Altwein JE, Klippel F, et al. Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. Cancer 1993; 72: 3878-9.
84. Boccardo F, Pace M, Rubagotti A, et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer 1993; 29 A: 1088-93.
85. Ferrari P, Castagnetti G, Ferrari G, Pollastri CA, Tavoni F, Dotti A. Combination treatment in M1 prostate cancer. Cancer 1993; 72: 3880-5.
86. Klijn JG, de Voogt HJ, Studer UE, Schroder FH, Sylvester R, De Pauw M. Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of met astatic prostate cancer. European Organization for Research and Treatment of Cancer-Genitourinary Group. Cancer 1993; 72: 3858-62.
87. Robinson MR. A further analysis of European Organization for Research and Treatment of Cancer protocol 30805. Orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol. Cancer 1993; 72: 3855-7.
88. Denis L, Smith PH, De Moura JL, et al. Orchidectomy vs. Zoladex plus flutamide in patients with met astatic prostate cancer. The EORTC GU Group. Eur Urol 1990; 18 (suppl 3): 34-40.
89. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An cverwiev of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-9.
90. Waxman J, Pandha H, Crawford ED, Labrie F, Quartry P. Anti androgen in treatment of prostate cancer: letter to editor. Lancet 1995; 346: 1030-1.
91. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126-30.
92. Daneshgari F, Crawford ED. Endocrine therapy of advanced carcinoma of prostate. Cancer 1993; 71: 1089-97.
93. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993; 72: 3888-95.
94. Kramolowski EV. The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 1988; 139: 1242-4.
95. Zagars GK, Sands ME, Pollack A, von Eschenbach AC. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome. J Urol 1994; 151: 1330-3.
96. van den Ouden D, Tribukait B, Blom JH, et al. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1993; 150: 400-6.
97. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235-46.
98. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen ablation: the flutamide ablation syndrome. J Urol 1993; 149: 607-9.
99. Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to flutamide ablation in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150: 908-13.
100. Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone ablation: implications for the management of androgen-independent prostate cancer. Urology 1996; 47(Suppl 1A): 61-9.
101. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex ablation: evidence for an antiandrogen ablation syndrome Urology 1994; 43: 408-10.
102. Dawson NA, McLeod DG, Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen ablation syndrome. J Urol 1995; 153: 1946-7.
103. Bissada NK, Kaczmarek AT. Complete remission of hormone refractory adenocarcinoma of the prostate in response to ablation of diethylstilbestrol. J Urol 1995; 153: 1944-5.
104. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992; 31: 2393-9.
105. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen ablation on the stem cell composition of the Shionogi carcinoma. Cancer Research 1990; 50: 2275-82.
106. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546-50.
107. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 1993; 71: 2782-90.
108. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45: 839-45.
109. Isaacs JT, Kyprianou N. Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. Urological Res 1987; 15: 133-8.
110. Rennie PS, Bruchovsky N, Coldman AJ. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J Steroidal Biochem Mol Biol 1990; 37: 843-7.
111. Furuya Y, Sato N, Akakura K, et al. Paracrine growth stimulation of androgen-responsive Shionogi Carcinoma 115 by its autonomous subline (Chiba Subline 2). Cancer Res 1990; 50: 4979-83.
112. Colombel M, Olsson CA, Ng PY, Buttyan R. Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Research 1992; 52: 4313-9.
113. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 1993; 7: 546-754.
114. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4.
115. Trapman J, Brinkmann AO. The androgen receptor in prostate cancer. Pathol Res Pract 1996; 19: 752-60.
116. Koivisto P, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification: a novel molecular mechanism endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest 1996; 226 (suppl): 57-63.